What does fair value adjustment of warrants mean?

Represents the periodic non-cash gain or loss resulting from the revaluation of outstanding warrant liabilities to their current fair market value. This adjustment reflects changes in the company's stock price and other valuation inputs, impacting net income without affecting cash flow.

Citius Oncology, Inc. CTOR Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

ImmunityBio, Inc.IBRX

$295.41M+65,840%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s fair value adjustment of warrants?: Citius Oncology, Inc. (CTOR) reported fair value adjustment of warrants of $905K in Q3 2025.
What does fair value adjustment of warrants mean?: Represents the periodic non-cash gain or loss resulting from the revaluation of outstanding warrant liabilities to their current fair market value. This adjustment reflects changes in the company's stock price and other valuation inputs, impacting net income without affecting cash flow.